Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 655064 in active lupus nephritis
jRCT2080223278Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in lupus nephritis (LN) and systemic lupus erythematosus (SLE) comparing BI 655064 + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Complete Renal Response at Week 52. Started Aug 2016; status: completed.
02
Drugs
BI 655064
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2080223278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223278.